When our team saw the recent reel questioning whether a world-class athlete endorsing a GLP-1 drug was proof of a medical need, or proof of a massive marketing payday, we knew this was a conversation that had to be held. The example at hand is Serena Williams, now serving as a celebrity patient ambassador for Ro’s GLP-1 program, and husband Alexis Ohanian sits on Ro’s board. Williams has publicly stated she lost over 31 pounds with the support of a GLP-1 medication, saying that “GLP-1 helped me enhance everything that I was already doing – eating healthy and working out.”
But what message does her campaign send to women, especially younger ones, when someone of her caliber chooses pharmaceutical support as part of her health journey? Does it help normalize the idea that optimizing health can include medical tools, or does it risk blurring the line between medical decision-making and marketing influence? And what responsibility do celebrity endorsers and pharmaceutical marketers share in how these narratives are framed?
Take a listen.
View this post on Instagram
On one hand, there is real value in destigmatizing medical therapies and acknowledging that bodies change, that metabolism is complex, and that for some individuals, diet and exercise alone are insufficient. A public figure saying, “I trained at the highest level, ate a clean diet … but my body wasn’t responding the way it used to,” as Williams has said, challenges the myth of total control. Some will view her message as empowering, a form of validation for patients who have struggled quietly.
Yet the optics are paradoxical. When someone elite, highly disciplined, visibly successful, and socially celebrated uses a drug to reduce weight, it can imply that even perfection is not enough, and that the “natural” body is flawed. It can reinforce the idea that to be acceptable, to be visible, one must intervene medically. For the next generation, especially young women, that is a heavy burden. The suggestion becomes: if Serena can’t “do it” on her own, what chance do ordinary people have without medication?
Bring the idea. We’ll help build the show. From planning and production to polish and launch, we turn expertise into content that looks professional, feels intentional, & gives your audience a reason to return.
Moreover, the financial and structural incentives behind such campaigns raise ethical questions. Williams is not simply patient and storyteller; she is officially Ro’s ambassador. Her husband is an investor. The alignment of medical advocacy and capital investment blurs lines. When medical endorsements and marketing merge, the message becomes less about health and more about market expansion.
It also raises equity concerns. GLP-1s are expensive and often inaccessible to patients without coverage or deep pockets. When marketing elevates a celebrity story, the risk is that those already marginalized feel they are failing not just at health, but at access. The narrative of “health through medicine” can overshadow the very real work of preventive care, community access, and structural determinants of health.
But these aren’t purely cynical critiques. The campaign does have merit. Williams’ openness pushes for dialogue. Her story may encourage some to seek evaluation when they’ve felt shame. Medication, in many cases, changes lives. The challenge is striking balance: highlighting medical tools without elevating them to universal necessity or moral ideal.
We must push for transparency in these narratives. Disclosures need to be clear, not buried. Celebrity endorsements of medical treatments should come with contextual education, discussion of side effects, cost, eligibility, and alternative options. The marketing should not replace counseling or physician judgment.
Healthcare is full of fine print, power plays, and rules physicians are expected to navigate without a map. This expert-led SoMeDocs resource covers contract review, PBMs, healthcare law, patient-physician relationships, and the issues shaping medical practice today.
We believe physicians, patient advocates, and media creators have a shared duty here. When featuring a medical celebrity campaign, especially in weight or body-related areas, we must ask: What is the implied standard? Who is excluded from this story? What harms may follow unintended messaging?
As we reflect on what Serena’s campaign symbolizes, we also acknowledge that medicine evolves, and stigma around medical interventions needs to shift. We do not dismiss the potential benefit of GLP-1s — they have a place in treating metabolic disease, obesity, and related conditions. But when they are dressed as aesthetic miracles and marketed by icons, we must scrutinize more closely.
Let this campaign be a catalyst, not a conclusion. Let us carry forward a deeper conversation about access, narrative responsibility, healthy self-image, and the intersection of medicine and marketing. Let the next generation hear not that their bodies are never enough, but that medical tools exist when truly needed — not as badges of failure.
In the end, we want the narrative to lean toward agency (educating, empowering, critiquing) rather than prescription. We want to honor patients’ struggles and physicians’ integrity above brand amplification. And if celebrities step into medical endorsement, they do so knowing that voices like ours will read between the lines, ask hard questions, and demand accountability.
Celebrity endorsements of medical treatments should come with contextual education, discussion of side effects, cost, eligibility, and alternative options. The marketing should not replace counseling or physician judgment.
